Location
Headquarters: Menlo Park, California, United States, North America
Region: California
Country: US
Continent: North America
About
GRAIL is a healthcare company focused on detecting cancer earlier using blood-based multi-cancer early detection tests. It develops the Galleri Test and leverages next-generation sequencing, population-scale clinical studies, and advanced data analysis to identify cancer signals before symptoms appear. The company aims to alleviate the global burden of cancer with a mission-driven approach and operates with a focus on early detection across diverse populations in the United States and beyond.
Grail develops the Galleri test, a blood-based multi-cancer early detection screening tool. The company utilizes next-generation sequencing and advanced data science to identify cancer signals before symptoms appear. Its primary customers include healthcare providers and health systems seeking to improve early cancer diagnosis.
GRAIL, Inc.
2016
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Series D
3400000000
50m-100m
private
NASDAQ:GRAL
nasdaq
Investors
Founders
Jeff Huber
Mostafa Ronaghi
Leadership
Charlotte Arnold — Head of Corporate Communications
Matthew Zehnder — Product Manager
Satnam Alag — Senior Vice President Software Engineering and Chief Security Officer
Robert Ragusa — Chief Executive Officer
Scott Osler — Vice President and Head of Employer Channel
Technology Stack
Products
Galleri® Multi-Cancer Early Detection Test: A blood-based test that screens for signals from more than 50 types of cancer to detect cancer early and predict its origin.
Funding rounds
Post Ipo Equity · $325M · (2025-10-20)
Post Ipo Equity · $110M · (2025-10-16) · Lead: Samsung C&T Corporation,Samsung Electronics
IPO · (2024-06-13)
